AKANNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
AKANDA CORP.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 9, 2026
$1.12−0.08 (-6.67%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
AKANDA CORP. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Reportable [Member] | $258.08K | $836.66K | $423.68K | $2.62M | $41.43K | $2.06K | – | 100.0% | -69.2% |
| Infrastructure [Member] | $258.08K | – | – | – | – | – | – | 100.0% | – |
| Distribution Segment [Member] | – | $836.66K | $423.68K | $101.78K | $41.43K | $2.06K | – | – | – |
| Reportable Segment [Member] | – | – | – | – | $41.43K | $2.06K | – | – | – |
| Cultivation Segment [Member] | – | – | $1.74M | $2.52M | – | – | – | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Akanda's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.